Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.
P-glycoprotein (P-gp) is an ATP-dependent integral plasma membrane efflux pump, expressed in abundance in brain capillary endothelial cells and astrocytes. P-gp contributes to the blood-brain barrier in limiting the influx and retention of a variety of lipophilic compounds, including unconjugated bilirubin. Several drugs block P-gp function and thereby enhance intracellular accumulation of P-gp substrates. In this study we proposed that pretreatment with drugs known to inhibit P-gp function in clinically relevant doses would alter the uptake of bilirubin in the brain of 32- to 36-d-old rats. In the first arm of the study, the animals received pretreatment with an i.v. infusion of either propanolol, erythromycin, verapamil, ceftriaxone, rifampin, or saline, 10 min before an i.v. bolus of 50 mg/kg bilirubin was given. Except for the erythromycin-treated rats, all treatment groups had significantly higher brain-to-serum bilirubin ratios than control animals (p < 0.05, Welch's t test). In the second arm of the study, treatment with either ceftriaxone or rifampin or saline i.v. preceded a 50 mg/kg i.v. bolus of radioactive bilirubin. Analysis of seven different brain regions by scintillation counting showed that the distribution patterns differed significantly between the study groups (p < 0.001, ANOVA), however, not in accordance with a kernicteric staining pattern. Because of limited knowledge of expression and function of P-gp and other membrane transport proteins in the newborn, the implications of this study remain to be seen. We speculate that drugs known to inhibit P-gp function may increase the risk of bilirubin encephalopathy in the hyperbilirubinemic infant.
Hankø
Erik
E
Department of Pediatrics, Rikshospitalet, N-0027 Oslo, Norway.
Tommarello
Steve
S
Watchko
Jon F
JF
Hansen
Thor W R
TW
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism; D001663:Bilirubin / Q000378:metabolism* / Q000633:toxicity; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000166:cytology / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000378:metabolism; D002443:Ceftriaxone / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism; D004917:Erythromycin / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D011433:Propranolol / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012293:Rifampin / Q000378:metabolism; D014700:Verapamil / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D004917:Erythromycin; D002443:Ceftriaxone; D011433:Propranolol; D014700:Verapamil; D001663:Bilirubin; D012293:Rifampin